romidepsin + carfilzomib

This is a **combination therapy** of romidepsin and carfilzomib, both of which are approved anticancer agents used investigationally together for relapsed or refractory lymphomas, particularly peripheral T-cell lymphoma (PTCL). **Romidepsin** is a histone deacetylase inhibitor that induces cell cycle arrest and apoptosis by altering gene expression. **Carfilzomib** is a proteasome inhibitor that disrupts protein homeostasis, leading to apoptosis of malignant cells. The combination aims to leverage potential additive or synergistic antineoplastic effects. Clinical studies have explored the safety, tolerability, and preliminary efficacy of this combination, typically in patients whose lymphomas have relapsed or are refractory to standard treatments. The combination has shown a manageable safety profile, with some activity observed, but in certain studies did not outperform existing therapies for PTCL[4][9][6][7].

Other names

Carfilzomib and Romidepsin combination